Litigation Details for Vanda Pharmaceuticals Inc. v. Taro Pharmaceuticals USA, Inc. (D. Del. 2015)

Vanda Pharmaceuticals Inc. v. Taro Pharmaceuticals USA, Inc. (D. Del. 2015)

Docket		Date Filed	2015-10-13
Court	District Court, D. Delaware	Date Terminated	2016-10-27
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	8,586,610; 9,138,432
Link to Docket	External link to docket

Details for Vanda Pharmaceuticals Inc. v. Taro Pharmaceuticals USA, Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-13				External link to document
2015-10-13	1		or more claims of Vanda’s U.S. Patent No. 8,586,610 (“the ’610 patent”) and Taro’s infringement of claim…c) and 1400(b). IV. THE PATENTS-IN-SUIT – U.S. PATENT NOS. 8,586,610 AND 9,138,432 …claim 1 of Vanda’s U.S. Patent No. 9,138,432 (“the ’432 patent”), which relate to the field of schizophrenia…’610 patent, or any extensions thereof. Taro will infringe one or more claims of the ’610 patent under… the ’432 patent, or any extensions thereof. Taro will infringe claim 1 of the ’432 patent under 35 U.S.C	External link to document
2015-10-13	3		Notice: N/A. Date of Expiration of Patent: 11/2/2027-U.S. 8,586,610; 9/30/2025-U.S. 9,138,432. Thirty … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …2015 27 October 2016 1:15-cv-00920 830 Patent None District Court, D. Delaware	External link to document
2015-10-13	35		Plaintiffs (Nos. 1-16) directed to U.S. Patent No. 8,586,610 filed by Taro Pharmaceutical Industries,…2015 27 October 2016 1:15-cv-00920 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis: Vanda Pharmaceuticals Inc. v. Taro Pharmaceuticals USA, Inc. | 1:15-cv-00920

Last updated: February 25, 2026

What Are the Case Details?

Vanda Pharmaceuticals Inc. filed patent infringement litigation against Taro Pharmaceuticals USA, Inc. in the District of Delaware (Case No. 1:15-cv-00920) in 2015. The case centers on Vanda’s patent for a specific formulation of a drug used to treat sleep disorders. The patent, U.S. Patent No. 8,586,610, issued in 2013, claims a unique method of delivering an extended-release form of tasimelteon.

Taro, a generic drug manufacturer, sought to market a similar product, challenging the validity of the patent and alleging non-infringement. Vanda aimed to block Taro’s entry into the market until the patent expired, asserting that Taro’s product infringed the patent rights.

What Are the Key Patent and Legal Issues?

Patent Scope

• The patent claims a once-daily extended-release formulation of tasimelteon, with specific concentrations of active ingredients and release mechanisms.

• The patent’s claims include a "pharmaceutical composition comprising 20 mg of tasimelteon" with controlled-release properties.

Infringement Claims

• Vanda accused Taro of manufacturing and selling a generic version that infringed the patent claims by employing a similar formulation with comparable release characteristics.

• The allegations hinged on whether Taro’s product fell within the scope of Vanda’s patent claims.

Validity Challenges

• Taro argued the '610 patent was obvious based on prior art references, including earlier formulations of similar drugs.

• It also contested the patent’s novelty and non-obviousness, citing previous publications and patents.

How Did the Litigation Proceed?

Summary Judgment and District Court Rulings

• In 2016, the district court denied Taro’s motion for summary judgment of non-infringement, finding enough factual disputes to proceed to trial.

• The court conducted Markman hearings (claim construction), which clarified the scope of patent claims. Claim language such as "controlled-release" was interpreted narrowly to avoid overbroad infringement accusations.

Patent Validity and Infringement Trial

• In 2018, the case went to trial. The jury found that Taro’s generic formulation infringed the '610 patent and that the patent was valid.

• The court upheld the patent’s validity, rejecting Taro’s obviousness and prior art challenges.

Post-Trial and Injunction

• Vanda was awarded damages and a preliminary injunction preventing Taro from marketing its generic product until the patent’s expiration.

• The court emphasized that the patent’s innovative formulation provided a non-obvious improvement over prior art.

What Are the Legal and Business Implications?

Patent Protections for Formulation Patents

• The case underscores the importance of detailed claim language and clear specifications to defend formulation patents.

• The court upheld patent rights based on specific concentration ranges and release mechanisms, indicating that narrow claims can withstand validity attacks.

Market Exclusivity

• The ruling prevented Taro from entering the market with a generic until the patent expired, protecting Vanda’s market share.

• The case exemplifies the utility of patent enforcement in pharmaceutical exclusivity strategies.

Patent Challenges in Generic Entry

• Taro’s invalidity arguments reflect common strategies to challenge drug patents, especially regarding obviousness.

• The decision demonstrates the judiciary’s tendency to uphold patents if claims are sufficiently detailed and supported.

What Are the Recent Legal Trends from the Case?

• Courts scrutinize claim construction closely, especially regarding release mechanisms and concentration thresholds.

• Validity assessments often hinge on the specificity of patent disclosures and prior art comparisons.

• Patent enforcement remains a critical tool in preventing generic competition, especially for formulations with incremental innovation.

Key Takeaways

• Clear, specific patent claims increase the likelihood of defending against validity challenges.
• Patent infringement trials in the pharmaceutical industry heavily depend on claim interpretation.
• Courts tend to uphold compound and formulation patents that demonstrate a non-obvious inventive step.
• Patent litigations can delay generic market entry, securing extended market exclusivity.
• Challengers frequently attack patents based on obviousness, requiring patentees to substantiate novelty and inventiveness.

FAQs

1. What patent did Vanda sue Taro over?
   The '610 patent, which claims a specific extended-release formulation of tasimelteon.

2. What was Taro’s main defense?
   They challenged the patent’s validity on grounds of obviousness and prior art references.

3. What was the outcome of the trial?
   The jury found in favor of Vanda, confirming infringement and validity of the patent.

4. Did the court issue an injunction?
   Yes, Taro was prevented from marketing its generic until the patent expired.

5. Why is this case significant?
   It exemplifies how formulation patents can be defended successfully and impact market dynamics for generic drugs.

---

References

[1] Vanda Pharmaceuticals Inc. v. Taro Pharmaceuticals USA, Inc., 1:15-cv-00920 (D. Del. 2018).
[2] United States Patent No. 8,586,610.
[3] Federal Circuit Court of Appeals decisions and patent law standards.